Compare Marsh & McLennan Companies, Inc. (MRSH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs GeneDx Holdings Corp — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.04 (market cap $87.77B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 48.8× GeneDx Holdings Corp's market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MRSH | WGS | |
|---|---|---|
Market Cap | $87.77B | $1.80B |
Sector | Financials | Technology |
52-Week High | $211.21 | $167.51 |
52-Week Low | $157.32 | $34.51 |
Enterprise Value | $108.61B | $1.80B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $181.59, down 0.32% on the day, with a bullish technical signal from moving averages and support at $180. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS versus $2.88 expected, driven by 6% revenue growth to $7.4 billion. Fundamentals show robust profitability with a 14.26% net margin and 27.42% ROE, while valuation ratios like P/E of 22.77 and P/S of 3.26 reflect premium pricing. Recent news highlights a 10% dividend increase to $0.99 per share, payable in August 2026.
The outlook for MRSH is positive, supported by consistent earnings beats and strategic AI investments, but risks include rising operating expenses and softer insurance pricing. Analysts maintain a consensus price target of $203.75, implying 12% upside, with 11 buy ratings outweighing 1 sell. Investors should monitor expense management and organic growth sustainability amid competitive pressures.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
